Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shibata, Yoshisato
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]	Active, not recruiting	2	216	Europe, Japan, US, RoW	LY3819469, Placebo	Eli Lilly and Company	Lipoprotein Disorder	10/23	10/24
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
JNIR, NCT02828917: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial	Completed	N/A	104	Japan	MedJ-01 Ridaforolimus Eluting Coronary Stent System	Medinol Ltd.	de Novo or Restenosis Lesions	06/18	08/22